Leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, malignant lymphoma, multiple myeloma
Conditions
Interventions
We evaluate 18F-FLT PET/MRI during the phase of pretransplant, engraftment and posttransplant day +180. We also evaluate whole bone marrow MRI in the posttransplant day +100 and +365.
Sponsors
University of Fukui
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Patients aged 20 years or older at the time of obtaining consent 2 Hematological malignancy (Leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, malignant lymphoma and multiple myeloma) patients who receive allogeneic hematopoietic cell transplantation 3 Patients who, after receiving a sufficient explanation for participating in this study, have a sufficient understanding and have the free written consent of the patient (or a deputy if a deputy is required)
Exclusion criteria
Exclusion criteria: 1 Patients who have Surgically implanted medical devices in the body (cardiac pacemaker, cochlear implant, vascular stent, arterial clip, prosthetic joint, dental implant, magnetic dentures, etc.) 2 Pregnant women or patients who may be pregnant 3 Other patients who the investigator determined to be inappropriate as subjects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to access the characteristics of hematopoiesis process in BM, PB and CB transplantation patients. We evaluate regularly the standardized uptake value of whole-body bone marrow used by 18F-FLT PET/MRI during the pretransplant and first posttransplant year. | — |
Countries
Japan
Contacts
Public ContactHiroaki Araie
University of Fukui Hospital Department of hematology and oncology
Outcome results
None listed